Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Verdiperstat · BHV-3241, AZD3241

Small molecule · developed by Biohaven

Phase 3 Most advanced trial (none active)

BHVN Developer

2 Registered trials

What is Verdiperstat?

Verdiperstat is an investigational small-molecule drug studied in Multiple System Atrophy, Multiple System Atrophy (MSA).

At a glance

Also known as: BHV-3241, AZD3241
Drug type: Small molecule
Therapy area: Neurology
Developer: Biohaven (BHVN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: TT3345YXVR

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03952806	Phase 3	Multiple System Atrophy	Completed	BHVN
NCT05086094	N/A	Multiple System Atrophy (MSA)	No longer available	BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple System AtrophyMultiple System Atrophy (MSA)

More from Biohaven

BHV-1300 Phase 3 BHV-1400 Phase 3 BHV-1530 Phase 1 BHV-2100 Phase 2 BHV-700 Phase 1 BHV-7000 Phase 2/3 BHV-8000 Phase 2/3 PBI-410 Phase 1/2 Talditercept Alfa Phase 3 Troriluzole Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHVN page.

Follow BHVN, the company behind Verdiperstat

See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHVN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z